Metabolomics platform ressources

The facility consists of two complementary chromatography/mass spectrometry systems as well as Mass Spectrometry Imaging:

• UHPLC U3000 Dionex - Orbitrap q-Exactive Thermo Scientific
• UHPLC 1290 Binary Pump Agilent - QQQ 6470 Agilent
• DESI-SYNAPT XS Waters

We also have a complete dedicated sample preparation room, equipped with -80°C freezer.

Metabolomics platform activities

Mass-spectrometry is the core technology of our facility enabling to measure all potential classes of metabolites for both exploratory and targeted approaches.

Exploratory metabolomics profiling is performed on a high resolution mass spectrometer (HRMS) coupled to ultra-high performance liquid chromatography (UHPLC).

Targeted metabolomics relies on multiple reaction monitoring (MRM) after separation by UHPLC, depending on the properties of the metabolites of interest.

Clinical trials

The objective of clinical trials is to improve patient care and treatment at all stages of disease. They assess the efficacy and safety of new treatments before these are offered to all suitable patients.

These new treatments may be new drugs, combinations of drugs, new ways of administering them or new treatment techniques (surgery, radiotherapy). Clinical studies may be initiated by the pharmaceutical industry, groups of cooperating centres or Gustave Roussy itself.

Team members

• Head of the genomic platform: Nathalie DROIN, PhD
  (nathalie.droin@gustaveroussy.fr)
• Marie BRECKLER, Technician
• Betty LEITE, Technician
• Audrey NAIMO, Technician
• Maëla FRANCILLETTE, engineer
• Béatrice FIET, assistant manager

Collective email address: GD-UGF@gustaveroussy.fr

Equipment

• 2 Bioanalyzer 2100 (Agilent)
• 1 FragmentAnalyzer (Agilent)
• 1 S220 Ultrasonicator (Covaris)
• 1 E220 Ultrasonicator (Covaris)

• 1 Robot Bravo (Agilent)
• 1 Robot SpriWorks (Beckman)

• 2 Chromium™ Controller (10X Genomics)
• 1 Tapestri (Mission Bio)

1 NovaSeq6000 (Illumina)

• 1 MiSeq (Illumina)
• 1 MiniSeq (Illumina)
• 1 PromethION 48 (Oxford Nanopore)

Gustave Roussy's US AMMICa Genomics Platform (INSERM US23 / CNRS UMS3655) aims to characterize cancers and experimental models using innovative genomic approaches.

Imaging and Cytometry Platform

• Cytometry & Mass imaging
• Microscopy
• Clinical Transfer Imaging